| Followers | 53 |
| Posts | 14470 |
| Boards Moderated | 0 |
| Alias Born | 06/15/2014 |
Thursday, August 14, 2025 7:20:36 AM
Thanks Sleven, and for the link a few posts back. Sounds like November we will know more about final approval and reimbursement. I was busy yesterday and am up early this morning in prep for my trip. Wifi will be spotty so I may check once in a while but probably not post for the next couple of weeks. Good luck.
Recent OCUL News
- Ocular Therapeutix™ to Host Investor Day on June 17, 2026 • GlobeNewswire Inc. • 06/02/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2026 08:08:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2026 08:07:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2026 08:06:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2026 08:05:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/26/2026 08:30:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/26/2026 08:27:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/26/2026 08:24:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/26/2026 08:21:24 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 12:46:18 PM
- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/15/2026 11:00:00 AM
- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/08/2026 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 11:28:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 11:06:45 AM
- Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights • GlobeNewswire Inc. • 05/05/2026 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 09:23:14 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 09:17:14 PM
- Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026 • GlobeNewswire Inc. • 04/28/2026 11:00:00 AM
- Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences • GlobeNewswire Inc. • 04/27/2026 11:00:00 AM
- Ocular Therapeutix™ to Host Investor Day on June 17, 2026 • GlobeNewswire Inc. • 04/22/2026 11:00:00 AM
- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/14/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 09:15:06 PM
- Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD • GlobeNewswire Inc. • 04/13/2026 11:00:00 AM
